ArticleDiabetology & metabolic syndrome2026
Benfotiamine promotes diabetic wound healing by modulating Trisk95 and reducing oxidative stress.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impaired wound healing in diabetic patients is a major clinical challenge, often associated with mitochondrial dysfunction and oxidative stress. Excessive ROS production increases inflammation and disrupts tissue regeneration. Current wound treatments primarily target infection control and wound closure, but do not address the underlying factors. Therefore, there is a critical need for therapies that target the underlying mechanisms sustaining impaired healing in diabetic wounds. This study investigates the therapeutic potential of benfotiamine in promoting diabetic wound healing by modulating Trisk95 expression and reducing oxidative stress. Molecular docking for benfotiamine-Trisk95 interaction and KEGG pathway analysis of benfotiamine-targeted genes were performed, which are related to diabetic complications. In vivo experimentation was conducted in diabetic mouse models, and benfotiamine was applied topically to the wounds to examine its effect on wound healing rate. The expression of Trisk95, IL-6, and IL-10 genes was analyzed, and antioxidant effects were evaluated by analyzing ROS levels. In in silico studies, molecular docking showed stable binding of benfotiamine to Trisk95, indicating a strong ligand–protein interaction. The KEGG analysis showed that benfotiamine-targeted genes are crucial mediators of oxidative stress and inflammation in diabetic complications and are linked to mitochondrial function. In vivo studies confirmed that Trisk95 expression is upregulated in diabetic mice as compared to non-diabetic mice. Further experiments showed that benfotiamine accelerates wound closure by significantly downregulating Trisk95 and IL-6, while upregulating IL-10 expression. Furthermore, benfotiamine increased the activity of antioxidant enzymes, including superoxide dismutase and Catalase, resulting in reduced ROS levels in wound tissues. In conclusion, these findings suggest that benfotiamine may be a potential candidate for promoting mitochondrial function and skin regeneration, which ameliorate wound healing in diabetic mice by modulating Trisk95 and exhibiting anti-inflammatory and antioxidant effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.